CBIO

NASDAQCrescent Biopharma, Inc.
High Tide · 68Squeeze · Watch 50BullishSmart Money · No dataSocial · No data 0
$19.41
$-0.05 (-0.26%)
15-min delayed · Sep 14, 2:20 AMReal-time

Score summary

Buy
Analyst Ratings
3Ratings
2 Buy1 Hold0 Sell
Tide Score
68
High Tide · stable · Top 11% of universe (4003)
Outlook69High Tide · stable · Top 13% of universe (4004)
Squeeze Score
50
Watch ·
  • Days to cover19.91
  • Short interest11.91% of float
  • Borrow rate137.57%
  • Short interest trend-1.06% (30d)
Trend
Bullish
Trending up — 4 of 8 indicators bullish
Recent Smart Money

Key statistics

Market Cap
$721.02M
52-week range
$8.94 – $26.98
117% from low
Day range
$19 – $20
Open $19.81
Volume
264k
vs 248k avg · 107%
P/E (TTM)
2.6
Fwd —
Earnings
Nov 5
52d · est $-0.71

Country ranks

US RankCountry rank populator pending
BW universe: US & CA common stocks only · ETFs and mutual funds excluded · Methodology →

Price chart with forecast cone and smart-money events

Wall Street Analyst Consensus

Wall Street Analyst Consensus
Aggregate of 3 third-party analyst opinions — not Quantellect advice.
12-mo median price target
$27
3 Wall St 12-month targets
High
$35
Average
$28
Low
$22
$9$16$23$29$36HIGH$35MEDIAN$27LOW$22Mar ’26NOW12-mo target
Recent price history, then Wall-Street analysts’ 12-month price targets (high / median / low) shown forward to the 12-month target levels. Targets are third-party analysts’ estimates of future performance — not guarantees, and not Quantellect recommendations. Past results do not guarantee future returns.
Per-analyst ratings are not yet available for this ticker.
Aggregate of third-party analysts’ published opinions, shown for information only — not Quantellect advice. The 67/100 Analyst Score (Buy) is Quantellect’ documented weighting of the rating distribution on the same 0–100 scale as the Tide / Squeeze / Trend / Money scores; the verdict label is derived from that score. Past results do not guarantee future returns. Source: aes.

Why Tide score breakdown

Smart-money feed

Social pulse

Smart-money modules

Catalysts ahead

Catalysts aheadEarnings Nov 5 (post-market, est EPS $-0.71) · Annual shareholder meeting Jun 17 · Russell 1000 rebalance Jul 22 · DOJ CUDA hearing window Q3

Drill deeper

Not investment advice. Past results do not guarantee future returns. Scores, narratives, and historical-cohort statistics on this page are generated by Quantellect algorithms from public filings, market data, and AI synthesis, and describe the historical performance of structurally similar setups in our universe; failures are included. Data may be 15-minute delayed, contain errors, or be revised. Always do your own research and consult a licensed financial advisor before making investment decisions.